The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Durable remission at 2 years following CAR-T axi-cel in refractory DLBCL
Yi Lin, MD, PhD, of the Mayo Clinic, Rochester, MN, shares the promising results from the 2-year follow up of the ZUMA-1 study (NCT02348216). In this trial, patients received the CD19-directed CAR T-cell therapy, axicabtagene ciloleucel. Of those who reached remission after 1 year, over 93% were still in remission after 2 years. In addition, two thirds of these patients still had detectable CAR T-cells in their circulation. Further analysis of high-risk subgroups found that some in this population were able to reach remission. This interview was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
